

For Immediate Release

May 27, 2016

**Dr. Lal PathLabs Limited posts revenue growth of 20% in FY16
Records growth of 15% in Q4 FY2015-16**

New Delhi, India, May 27, 2016 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the financial year 2015-16 in accordance with Indian GAAP.

Consolidated Performance Highlights: Q4FY2016 vs. Q4FY2015

- Operating Revenue increased by 15% Y-o-Y to Rs. 1977 million
- EBITDA increased by 16% Y-o-Y to Rs.520 million without considering ESOP charge reversals. After ESOP charge reversals, the EBITDA for the quarter increased to Rs 554 million (growth of 25%)
- EBITDA Margin was 26.3% for Q4 without considering ESOP reversals.
- Profit after Tax increased by 20% to Rs. 346 million; Margins of 17.5%

Consolidated Performance Highlights: FY2015-16 vs. FY2014-15

- Operating Revenue increased by 20% Y-o-Y to Rs. 7913 million
- EBITDA increased by 15% Y-o-Y to Rs.2113 million without considering reversal of ESOP charges;
- Profit after Tax increased by 38% to Rs. 1332 million; PAT Margin of 16.8%
- EPS for the year was Rs 16.00
- Dividend proposed @ Rs 2.45 per equity share of Rs 10 each

Commenting on the results and performance, **Dr. Arvind Lal, Chairman and Managing Director** said:

I am delighted to share the first annual financial and operating results of the Company as a listed entity. I am pleased to inform that our persistent pursuit and efforts to grow our brand and provide better diagnostic services to a nation where there is an immense and urgent need for quality healthcare, has translated in us not only fulfilling our passion but has also generated positive results. Our continuous initiatives to innovate and expand have enabled us stay ahead on our growth curve, in a sector which we believe is highly dynamic and competitive

I am happy to announce that all of us at LPL have built a strong scalable business which has grown at a robust 20% last year. The PAT has grown to Rs 1332 mn with a margin of 16.8%. I am pleased to inform that the Board is recommending a dividend for the year at Rs 2.45 per equity share of Rs 10 each.

The revenue growth was driven by 21% volume growth with nearly 12 mn patients being tested.

We are confident that with the support and commitment of our teams we will continue to deliver high quality services to our patients and drive growth and create significant value for all our stakeholders.

Financial Overview

Particulars (Rs mn)	Q4 FY 16	Q4 FY 15	Gr %	12M FY 16	12M FY 15	Gr %
Revenue	1,977	1,718	15%	7,913	6,596	20%
Other Income	13	12	12%	50	30	70%
Total Revenue	1,990	1,730	15%	7,963	6,625	20%
Total Expenditure	1,436	1,286	12%	5,816	5,036	15%
ESOP	(35)	5		(35)	242	
EBITDA with ESOP reversal	554	444	25%	2,148	1,589	35%
EBITDA without ESOP reversal	520	449	16%	2,113	1,831	15%
Margins	28.0%	25.8%		27.1%	24.1%	
Margins without ESOP	26.3%	26.1%		26.7%	27.8%	
PBT after ESOP reversal	528	390	35%	2,007	1,397	44%
PBT without ESOP reversal	493	395	25%	1,973	1,639	20%
Margins	26.7%	22.7%		25.4%	21.2%	
Margins without ESOP	24.9%	23.0%		24.9%	24.9%	
PAT	346	288	20.5%	1,332	964	38%
Margins	17.5%	16.7%		16.8%	14.6%	
EPS (Diluted)	4.14	3.48		15.98	11.65	

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi, 171 other clinical laboratories, 1,559 patient service centers and nearly 5,000 pickup points as of March 31, 2016. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Rajat Kalra

+91 124 3016500

Dr. Lal PathLabs Limited

Rajat.Kalra@lalpathlabs.com

Aparna Agarwal

+919811177405

Adfactors PR

aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.